Adaptive Trials Simulation Toolkit Addresses New Ways to Run Clinical Trials
Adaptive Trials Simulation Toolkit Addresses New Ways to Run Clinical Trials
Tessella (Newton, MA) Adaptive Trials Simulation Toolkit contains a range of adaptive clinical trial models for simulating different adaptive methods from Phase I through Phase III. The first release includes a NDLM dose finder and a Seamless Phase II/III Simulator.
Adaptive Trials Simulation Toolkit
The NDLM dose finder, specific to Phase II trials, simulates trials run using a Bayesian Model that is updated with response data as the trial runs. The NDLM is fitted to the response data and used to estimate whether any dose will fit the target criteria and which dose is most likely. It allows the model to recommend whether to continue the trial and which doses to favor in randomization.
Seamless Phase II/III Simulator offers an interim analysis between the two phases, where the treatment arms to be retained are selected and the sample size for the next phase calculated. This step saves time between Phase II and III, and allows for smaller Phase III trials.
Tessella, (617) 454-1220, www.tessella.com
Walgreens, Boehringer Ingelheim Agree to Collaboration on Enhancing Clinical Trial Diversity
May 2nd 2024Partnership expected to utilize Walgreens’ pharmacies as recruitment and trial sites for a clinical study regarding obesity, weight issues, and type 2 diabetes, mainly in historically underrepresented groups.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.